Fulgent Genetics, Inc. (FLGT) Presents at UBS Global Healthcare Conference 2025 Transcript

Lu Li
UBS Investment Bank, Research Division

Great. Well, our next session is the management team from Fulgent Genetics. We are very lucky to join by Paul Kim and Brandon Perthuis. Paul and Brandon. Welcome.

Brandon Perthuis
Chief Commercial Officer

Thank you. Thanks for having us.

Lu Li
UBS Investment Bank, Research Division

Great. So you guys reported last Friday. Why not give us a quick kind of overview and then highlights of the quarter and then anything that you wanted to flag to the audience?

Paul Kim
Chief Financial Officer

Yes, I’ll start with the financials, and I’ll turn it over to business who can color in where we sit from a business standpoint and our outlook going forward. So we reported a quarter of $84.1 million. Revenue came in higher than what we anticipated internally as well as what the Street was anticipating. Our gross margins also came in favorably as well as the other key financial metrics. We had a non-GAAP income for the quarter. And we raised guidance from $320 million to $325 million. We think that we’re going to be finishing the year on a very strong note from a financial sense, and then Brandon can color in the status of the business.

Brandon Perthuis
Chief Commercial Officer

Yes. I mean that was a good financial overview. I mean the business performed well, as Paul mentioned, above our expectations. So I mean, all 3 business areas are performing well. We break it down into Precision Diagnostics, Anatomic Pathology and our Biopharma Services. Precision Diagnostics was up nicely. Biopharma Services was up nicely. We had a